Form 4: Sangamo Therapeutics CEO Sandy Macrae Reports Share Disposition for Tax Obligations
SEC Form 4
CEO Sandy Macrae disposed of shares to cover tax obligations related to vested restricted stock units, while still holding a significant number of shares.
Summary
- On April 22, 2025, Sandy Macrae, the CEO and a director of Sangamo Therapeutics, disposed of 126,950 shares of common stock at a price of $0.7763 per share.
- This disposition was solely for mandatory tax withholding purposes related to the vesting of a portion of a restricted stock unit (RSU) grant.
- Following the transaction, Macrae still beneficially owns 2,325,898 shares of Sangamo Therapeutics common stock.
- These shares include those resulting from the April 22, 2025 vesting installment of a January 22, 2024 RSU grant, shares subject to a February 24, 2023 RSU grant, and shares subject to a February 25, 2025 RSU grant, all vesting over time.
Sentiment
Score: 6
Explanation: Neutral sentiment as the filing reflects a routine transaction for tax purposes and doesn't indicate a change in the CEO's overall confidence in the company.
Positives
- The CEO continues to hold a substantial number of shares, indicating confidence in the company's future.
- The vesting of RSUs incentivizes the CEO to remain with the company and drive performance.
Future Outlook
The CEO's remaining RSUs will continue to vest in installments through January 22, 2026, February 24, 2026 and beyond, subject to continuous service.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Comparison to Industry Standards
- Executive compensation packages often include RSUs to align management's interests with shareholders, a common practice among publicly traded biotechnology companies.
- Tax-related share dispositions are a routine part of RSU vesting and are not necessarily indicative of a change in the executive's long-term outlook for the company.
- Comparable companies such as CRISPR Therapeutics and Editas Medicine also utilize RSU grants as part of their executive compensation packages.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine tax-related disposition.
- The CEO's continued holding of a significant number of shares signals ongoing commitment to the company.
Key Dates
| Date | Description |
|---|---|
| 01/22/2024 | Date of RSU grant, vesting in installments through January 22, 2026. |
| 02/24/2023 | Date of RSU grant, vesting in installments through February 24, 2026. |
| 02/25/2025 | Date of RSU grant, vesting as to one-fourth of the shares on February 25, 2026, and the remainder in 8 successive equal quarterly installments thereafter. |
| 04/22/2025 | Date of share disposition for tax withholding related to RSU vesting. |
| 04/24/2025 | Date of signature on the Form 4 filing. |
Keywords
Sangamo Therapeutics, Sandy Macrae, CEO, Form 4, Share Disposition, Restricted Stock Units, RSU, Tax Withholding, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.